JLE

L'Information Psychiatrique

MENU

Utilisation des antipsychotiques chez l’enfant et l’adolescent : données actuelles Volume 94, numéro 2, Février 2018

  • [1] Acquaviva E., Legleye S., Auleley G.R. Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data. BMC Psychiatry. 2009;9:72.
  • [2] Acquaviva E., Peyre H., Falissard B. Panorama de la prescription et de la consommation des psychotropes chez l’enfant et l’adolescent en France. Neuropsychiatr Enfance Adolesc. 2012;60:77-85.
  • [3] Desjardins J., Lafortune D., Cyr F. La pharmacothérapie dans les centres de rééducation : portrait des enfants placés qui reçoivent des services médicaux. Psychiatr Enfant. 2010;53:285-312.
  • [4] Pringsheim T., Hirsch L., Gardner D., Gorman D.A. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2 : antipsychotics and traditional mood stabilizers. Can J Psychiatry Rev Can Psychiatr. 2015;60:52-61.
  • [5] McQuire C., Hassiotis A., Harrison B., Pilling S. Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis. BMC Psychiatry. 2015;15:303.
  • [6] Mandell D.S., Morales K.H., Marcus S.C. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics. 2008;121:e441-448.
  • [7] Aman M., Rettiganti M., Nagaraja H.N. Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism : 21-Month Follow-up After 8-Week Placebo-Controlled Trial. Adolesc Psychopharmacol. 2015;25:482-493. J Child
  • [8] Kent J.M., Kushner S., Ning X. Risperidone dosing in children and adolescents with autistic disorder : a double-blind, placebo-controlled study. J Autism Dev Disord. 2013;43:1773-1783.
  • [9] Mohiuddin S., Ghaziuddin M. Psychopharmacology of autism spectrum disorders : a selective review. Autism Int J Res Pract. 2013;17:645-654.
  • [10] Hirsch LE, Pringsheim T. “Aripiprazole for autism spectrum disorders (ASD)”. In : Cochrane Database of Systematic Reviews [Internet]. Hoboken (NJ, EU) : John Wiley & Sons, 2016 [cité 16 oct 2016]. Disponible sur onlinelibrary.wiley.com/doi/10.1002/14651858.CD009043.pub3/pdf.
  • [11] Findling R.L., Mankoski R., Timko K. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry. 2014;75:22-30.
  • [12] Hellings J.A., Reed G., Cain S.E. Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability. Adolesc Psychopharmacol. 2015;25:150-159. J Child
  • [13] Loebel A., Brams M., Goldman R.S. Lurasidone for the Treatment of Irritability Associated with Autistic Disorder. J Autism Dev Disord. 2016;46:1153-1163.
  • [14] Owen R., Sikich L., Marcus R.N. Aripiprazole in the treatment of irritability in children and adolescents with autiséic disorder. Pediatrics. 2009;124:1533-1540.
  • [15] Snyder R., Turgay A., Aman M. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41:1026-1036.
  • [16] Ghanizadeh A., Sahraeizadeh A., Berk M. A head-to-head comparison of aripiprazole and rispéridone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev. 2014;45:185-192.
  • [17] Ercan E.S., Uysal T., Ercan E. Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study. Pharmacopsychiatry. 2012;45:13-19.
  • [18] Findling R.L., McNamara N.K., Branicky L.A. A double-blind pilot study of rispéridone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:509-516.
  • [19] Connor D.F., McLaughlin T.J., Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. Adolesc Psychopharmacol. 2008;18:140-156. J Child
  • [20] Findling R.L., Reed M.D., O’Riordan M.A. Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:792-800.
  • [21] Krieger F.V., Pheula G.F., Coelho R. An open-label trial of rispéridone in children and adolescents with severe mood dysregulation. Adolesc Psychopharmacol. 2011;21:237-243. J Child
  • [22] Gadow K.D., Brown N.V., Arnold L.E. Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone : 12-Month Follow-Up of the TOSCA Trial. J Am Acad Child Adolesc Psychiatry. 2016;55:469-478.
  • [23] Masi G., Milone A., Manfredi A. Combined pharmacotherapy-multimodal psychotherapy in children with Disruptive Behavior Disorders. Psychiatry Res. 2016;238:8-13.
  • [24] Shain B.N. Pediatric Bipolar Disorder and Mood Dysregulation : Diagnostic Controversies. Adolesc Med State Art Rev. 2014;25:398-408.
  • [25] Perlis R.H., Miyahara S., Marangell L.B. Long-term implications of early onset in bipolar disorder : data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2004;55:875-881.
  • [26] Tohen M., Vieta E., Goodwin G.M. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania : a randomized, 12-week, double-blind study. J Clin Psychiatry. 2008;69:1776-1789.
  • [27] Findling R.L., Nyilas M., Forbes R.A. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70:1441-1451.
  • [28] Haas M., DelBello M.P., Pandina G. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder : a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009;11:687-700.
  • [29] Findling R.L., Cavuş I., Pappadopulos E. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. Adolesc Psychopharmacol. 2013;23:545-557. J Child
  • [30] Tramontina S., Zeni C.P., Ketzer C.R. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry. 2009;70:756-764.
  • [31] Pathak S., Findling R.L., Earley W.R. Efficacy and Safety of Quetiapine in Children and Adolescents With Mania Associated With Bipolar I Disorder : A 3-Week, Double-Blind, Placebo-Controlled Trial. J Clin Psychiatry. 2013;74:e100-e109.
  • [32] DelBello M.P., Kowatch R.A., Adler C.M., Stanford K.E., Welge J.A., Barzman D.H. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2006;45:305-313.
  • [33] Pavuluri M.N., Henry D.B., Findling R.L. Double-blind randomized trial of rispéridone versus divalproex in pediatric bipolar disorder. Bipolar Disord. 2010;12:593-605.
  • [34] Detke H.C., DelBello M.P., Landry J., Usher R.W. Olanzapine/Fluoxetine Combination in Children and Adolescents With Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Trial. J Am Acad Child Adolesc Psychiatry. 2015;54:217-224.
  • [35] Findling R.L., Pathak S., Earley W.R., Liu S., DelBello M.P. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial. Adolesc Psychopharmacol. 2014;24:325-335. J Child
  • [36] Findling R.L., Youngstrom E.A., McNamara N.K. Double-blind, randomized, placebo-controlled long-term maintenance study of aripiprazole in children with bipolar disorder. J Clin Psychiatry. 2012;73:57-63.
  • [37] Burd L., Kerbeshian J. A North Dakota prevalence study of schizophrenia presenting in childhood. J Am Acad Child Adolesc Psychiatry. 1987;26:347-350.
  • [38] Clemmensen L., Vernal D.L., Steinhausen H.-C. A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry. 2012;12:150.
  • [39] Findling R.L., Robb A., Nyilas M. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165:1432-1441.
  • [40] Haas M., Unis A.S., Armenteros J. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of rispéridone in adolescents with schizophrenia. Adolesc Psychopharmacol. 2009;19:611-621. J Child
  • [41] Kryzhanovskaya L., Schulz S.C., McDougle C. Olanzapine versus placebo in adolescents with schizophrenia : a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48:60-70.
  • [42] Savitz A.J., Lane R., Nuamah I., Gopal S., Hough D. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. J Am Acad Child Adolesc Psychiatry. 2015;54:126-37.e1.
  • [43] Singh J., Robb A., Vijapurkar U., Nuamah I., Hough D. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry. 2011;70:1179-1187.
  • [44] Findling R.L., McKenna K., Earley W.R., Stankowski J., Pathak S. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. Adolesc Psychopharmacol. 2012;22:327-342. J Child
  • [45] Sikich L., Frazier J.A., McClellan J. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420-1431.
  • [46] Kumra S., Frazier J.A., Jacobsen L.K. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996;53:1090-1097.
  • [47] Kumra S., Kranzler H., Gerbino-Rosen G. Clozapine versus « high-dose » olanzapine in refractory early-onset schizophrenia : an open-label extension study. Adolesc Psychopharmacol. 2008;18:307-316. J Child
  • [48] Pope S., Zaraa S.G. Efficacy of Long-Acting Injectable Antipsychotics in Adolescents. Adolesc Psychopharmacol. 2016;26:391-394. J Child